How many infections does tigecycline treat effectively?

Tigecycline treats infections caused by many Gram-positive and Gram-negative bacteria, but its use is reserved for cases where other antibiotics fail.

How does tigecycline kill bacteria?

Tigecycline stops bacteria from making proteins they need to live. It binds to the 30S subunit of bacterial ribosomes and blocks aminoacyl-tRNA from reaching the site where proteins are assembled.

How long does the approved treatment course last?

The FDA approves tigecycline for 5–14 days of therapy. Doctors adjust duration based on infection site and severity.

What infections does the FDA approve it for?

The FDA approves tigecycline for complicated skin and skin-structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia. These approvals rest on clinical trials showing non-inferiority to comparator antibiotics.

What infections does it cover that other antibiotics do not?

Tigecycline covers many multidrug-resistant organisms, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacteria. It also covers atypicals like Legionella pneumophila and Mycoplasma pneumoniae.

What side effects are patients asking about?

Patients often report nausea, vomiting, and diarrhea. The FDA has placed a black-box warning on increased all-cause mortality in patients who received tigecycline compared with other antibiotics.

What happens if the infection comes back after treatment?

Recurrence rates vary by infection type. Clinical studies show 6–15% of patients need retreatment or extension of therapy after the approved course.

When does the patent expire?

Tigecycline’s compound patent expired in the US in 2015. Generic versions entered the market after 2015, lowering prices and widening access.

When does regulatory exclusivity end?

Tivicay’s regulatory exclusivity ended in 2014. Generic manufacturers now produce tigecycline as a generic medicine under multiple ANDAs.

Who makes tigecycline?

Wyeth originally developed it. Pfizer acquired Wyeth and holds the current marketing authorization. Several Indian and Chinese manufacturers supply generics.

Can biosimilars enter before patent expiry?

Tigecycline is a small-molecule antibiotic, not a biological product. Biosimilars do not apply to antibiotics.